BioGenCell Ltd. appoints New Chair and Strengthens Board of Directors

BioGenCell, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat various severe vascular diseases, today announces that Detlef Krawinkel has been appointed to the role of Chairman. BioGenCell also announced the appointment of Zeev Milbauer to its Board of Directors.
 
During his career, Detlef Krawinkel has built up extensive expertise in most areas of drug development and commercialization, including general management, R&D, marketing, global fundraising, portfolio development, corporate partnerships and equity financing, driving value of various companies. He has been CEO of Accelero since 2015. In this role he advises growing companies, and helps guide the CEO and the board by giving them access to knowledge, expertise and resources.
 
Prior to Accelero, Detlef was CEO at Medoderm, a company, in the discovery, development and delivery of a novel therapeutic for the treatment of advanced wound care. Before he served as Head Western Europe of Alexion Pharmaceutical, focusing on the launch of various rare disease indications, and as the leader of the Hematology Franchise at Hoffmann-La Roche. Before he held a number of senior strategic and commercial roles in North America and Europe.
 
Detlef Krawinkel, newly appointed Chairman of BioGenCell said, “I look forward to working with the BioGenCell Executive Team and new Board colleagues as we build on BioGenCell’s achievements to date. I firmly believe that the Company’s innovative autologous cell therapy and strategic approach can yield a transformational therapy that fully addresses the significant unmet need of patients with vascular diseases.”
 
Yael Porat, CEO and Co-Founder of BioGenCell added, “The team at BioGenCell are very excited to welcome Detlef as Chairman. Detlef has a proven track record of success in a range of Senior Executive positions. We look forward to leveraging his experience as we progress patient recruitment for our Phase I/II clinical trial , on our lead programme in Critical Limb Ischemia. Detlef’s expertise will prove an invaluable asset to the company as we progress our operations.”
 
The newly appointed director, Mr. Zeev Milbauer brings over 30 years of extensive experience in the field of business development, finance and investment banking. Among his diverse roles he served as partner, finance advisor, trading broker and corporate guide to a variety of investment banking funds and companies. Zeev was CEO and partner for IBI, an investment banking company, Chief Financial Officer of trade, Manager of trust Fund Investments and Chairman of the non-bank stock exchange organization where he dealt with investment banking, financial consulting and corporate guidance in preparation for an IPO. His experience and responsibilities included among others, CEO and owner of a company. Mr. Zeev Milbauer currently holds director in RIT Capital Partners, Mirland Development and Minovia Therapeutics, a cell therapy biotech company.
 
About BioGenCell
 
BioGenCell is a clinical-stage regenerative medicine company developing a disruptive technology platform for automated production of patient specific autologous cell therapies, with initial focus on vascular diseases.

The company’s proprietary technology TRACT (Tissue Regenerative Activated Cell Therapy) is based on an unprecedented combination of the power of immunology and stem cell therapy providing personalized regenerative treatment for damaged tissues. The leading product BGC 101, is a highly innovative autologous cell therapy that is being studied in clinical programs in patients with chronic limb-threatening ischemia (CLI), a poorly treated disease with a high risk of amputation and death.

BGC- 101 has been shown to be both safe and effective, alleviating CLI in the majority of patients, offering the potential to reduce the need for amputation and increase the quality of life of CLI patients. BioGenCell is developing BGC-101 in a range of other indications and, pending approval, intends to launch and market this specialty product in all major territories.

BioGenCell is a privately-owned company, which draws on an exceptional understanding of the fundamental science of autologous cell therapies developed over the last decade.

The Company was founded in 2008 and is headquartered in Tel Aviv, Israel with a European Operations in Belgium.

To read more People News articles, click here.